芪苈强心胶囊联合琥珀酸美托洛尔缓释片对扩张型心肌病患者左室射血分数及运动耐力影响

Effect of Qiliqiangxin capsule combined with metoprolol sustained release tablet on left ventricular ejection fraction and exercise endurance in patients with dilated cardiomyopathy

目的扩张型心肌病为临床常见疾病,对我国居民健康造成严重影响,目前,临床主要采用药物治疗,不同方案疗效各异。本研究探讨芪苈强心胶囊联合琥珀酸美托洛尔缓释片对扩张型心肌病患者左室射血分数及运动耐力的影响。方法选取2018-02-01—2018-12-01新乡市中心医院收治的82例扩张型心肌病患者为研究对象,根据患者性别、年龄、病程、心功能、心率和病因分类组间具有可比性的原则,在不同治疗方案中选择观察组与对照组,每组41例。对照组在常规治疗基础上给予琥珀酸美托洛尔缓释片治疗,观察组给予芪苈强心胶囊联合琥珀酸美托洛尔缓释片治疗。治疗3个月后,观察两组临床疗效、治疗前后脑钠肽(brain natriuretic peptide,BNP)水平、左室舒张末期内径(left ventricular end diastolic dimension,LVEDD)、左室射血分数(left ventricular ejection fraction,LVEF)、左室收缩末期内径(left ventricular end systolic diameter,LVESD)及血清运动耐力。结果治疗3个月后观察组总有效率为92.68%,高于对照组的75.61%,χ~2=4.479,P=0.034;观察组血清BNP水平为(258.10±32.01)pg/mL,低于对照组的(327.54±38.22)pg/mL,t=8.919,P<0.001;观察组LVEDD和LVESD分别为(51.28±4.40)和(41.15±4.10)mm,低于对照组的(56.89±5.67)和(47.66±4.56)mm,t值分别为5.005和3.798,均P<0.001;观察组LVEF为(59.86±4.32)%,高于对照组的(52.69±3.77)%,t=8.007,P<0.001;观察组6 min步行试验(6-minute walking test,6MWT)为(326.78±50.62)m,远于对照组的(301.32±47.69)m,t=2.344,P=0.022。结论芪苈强心胶囊联合琥珀酸美托洛尔缓释片治疗扩张型心肌病,疗效确切,并可显著改善心功能,提高运功耐力。

OBJECTIVE Dilated cardiomyopathy is a common clinical disease,which has a serious impact on the health of the people in China.At present,drug therapy is mainly used in clinic,and the curative effect of different schemes is different.This study investigate thes effect of Qiliqiangxin capsule combined with metoprolol succinate sustained-release tablets on left ventricular ejection fraction and exercise endurance in patients with dilated cardiomyopathy.METHODS The patients with dilated cardiomyopathy admitted to our hospital from February 1,2018 to December 1,2018 were selected as subjects.According to the principle of comparability,gender,age,course of disease,cardiac function,heart rate and etiology were classified.In the different treatment options,the observation group and the control group were selected,with 41 cases in each group.All patients were treated with conventional therapy,and the control group was treated with metoprolol succinate sustained-release tablets.The observation group were treated with Qiliqiangxin capsule and metoprolol succinate sustained-release tablets.After 3 months of treatment,the clinical efficacy of the two groups was observed and analyzed.The level of brain natriuretic peptide(BNP)and left ventricular end diastolic dimension(LVEDD),left ventricular ejection fraction(LVEF),Left ventricular end systolic diameter(LVESD),serum exercise tolerance were compared.RESULTS After 3 months of treatment,the total effective rate of the observation group was 92.68%,higher than that of the control group(75.61%),χ~2=4.479,P=0.034;the serum BNP level of the observation group was(258.10±32.01)pg/ml,lower than that of the control group(327.54±38.22)pg/ml,t=8.919,P<0.001;The LVEDD and LVESD of the observation group were(51.28±4.40)and(41.15±4.10)mm,lower than those of the control group(56.89±5.67)and(47.66±4.56)mm,t values were 5.005 and 3.798,both P<0.001;The LVEF of the observation group was(59.86±4.32)%,higher than that of the control group(52.69±3.77)%,t=8.007,P<0.001;The 6-minute walking test(6 MWT)of the observation group was(326.78±50.62)m,farther than that of the control group(301.32±47.69)m,t=2.344,P=0.022.CONCLUSION Qiliqiangxin capsule combined with metoprolol succinate sustained-release tablets is effective in the treatment of patients with dilated cardiomyopathy,and can significantly improve cardiac function and exercise endurance.